Summary
Pramlintide (Symlin) is an FDA approved injectable analog (lab-made version) of amylin, the hormone released with insulin that slows gastric emptying (how fast food leaves the stomach) and suppresses glucagon, a blood sugar raising hormone, after meals. Approved in March 2005 as an add-on to mealtime insulin in type 1 and type 2 diabetes, it lowers HbA1c (a measure of average blood sugar over about 3 months) by roughly 0.3 to 0.4 percentage points more than placebo over a year and produces about 1 to 2 kg of weight loss instead of the weight gain seen with insulin alone. It carries a boxed warning, FDA's most serious label warning, for severe insulin induced hypoglycemia (low blood sugar) and is prescription only.
What is Pramlintide?
Pramlintide is a synthetic 37 amino acid analog of human amylin (three proline substitutions to prevent aggregation). It is also known as Symlin, SymlinPen, Pramlintide acetate, AC137, Synthetic amylin analog.
How does it work?
Pramlintide acts at amylin receptors (calcitonin receptor with RAMP proteins) in the brainstem area postrema. This slows gastric emptying, suppresses inappropriate post meal glucagon secretion, and reduces food intake through central satiety signaling. It has no direct effect on insulin secretion or action. Human amylin aggregates into amyloid fibrils; the three proline substitutions in pramlintide prevent that so it can be formulated for injection.
| Cluster | Metabolic and growth hormone axis; also on the GLP-1 hub |
|---|---|
| Routes | Subcutaneous injection before major meals (pen device) |
| Conditions studied | Obesity and chronic weight management; Type 2 diabetes; Type 1 diabetes |
| Record | v3, draft, verified Sep 23, 2026 |
FDA-approved uses of Pramlintide
Yes. Symlin was approved in March 2005. Its label covers adjunctive (add-on) treatment of type 1 or type 2 diabetes in patients who use mealtime insulin and have not reached glucose goals despite optimal insulin therapy. It is the only amylin analog (lab-made version of the hormone amylin) approved in the US, it is prescription only, and it is not approved for weight loss. [4]
What does the evidence say about Pramlintide?
Multiple 1 year randomized placebo controlled trials as an add-on to insulin. Whitehouse 2002 (type 1 diabetes, n = 480, 52 weeks): HbA1c fell about 0.4 points on pramlintide versus 0.1 on placebo with a weight difference of about 1 kg. Hollander 2003 (type 2 diabetes on insulin, n = 656, 52 weeks): 120 ug twice daily lowered HbA1c by 0.62 points versus 0.22 with placebo and reduced weight by 1.4 kg versus a 0.7 kg gain. Aronne 2007 (obesity without diabetes, n = 204, 16 weeks): dose escalation to 240 ug three times daily produced about 3.6 kg placebo corrected weight loss.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 3 | 1340 |
| Human observational studies | 0 | n/a |
| Animal studies | 0 | n/a |
| All indexed studies | 3 | 1,340 |
Human evidence
Whitehouse 2002: 480 adults with type 1 diabetes randomized to pramlintide 30 or 60 ug with meals or placebo added to insulin for 52 weeks; HbA1c reduction was greater with pramlintide (about 0.4 versus 0.1 percentage points) and weight was about 1 kg lower, with more nausea and severe hypoglycemia in the first weeks. Hollander 2003: 656 insulin treated adults with type 2 diabetes; 120 ug twice daily reduced HbA1c by 0.62 versus 0.22 points and weight by 1.4 kg versus a 0.7 kg gain over 52 weeks, with insulin doses unchanged. Aronne 2007: 204 obese adults without diabetes; pramlintide up to 240 ug three times daily produced placebo corrected weight loss of about 3.6 kg at 16 weeks with nausea as the main adverse effect. Pramlintide is also the template for cagrilintide, the long acting amylin analog now in phase 3 with semaglutide.
Animal evidence
Rodent studies established amylin's effects on gastric emptying, glucagon suppression, and food intake, and showed that pramlintide reproduces them without forming amyloid. Animal data are supportive; the evidence base is human.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes2002 PMID 11919132 | Randomized, double blind, placebo controlled trial, 52 weeks, with open label extensionn = 480 Adults with type 1 diabetes on insulin | Greater HbA1c reduction (about 0.4 versus 0.1 percentage points) and about 1 kg lower weight than placebo | Evidence: Human RCT evidence |
| Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial2003 PMID 12610038 | Randomized, double blind, placebo controlled trial, 52 weeksn = 656 Insulin treated adults with type 2 diabetes | 120 ug twice daily lowered HbA1c by 0.62 versus 0.22 points and weight by 1.4 kg versus a 0.7 kg gain | Evidence: Human RCT evidence |
| Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study2007 PMID 17504894 | Randomized, double blind, placebo controlled dose escalation trial, 16 weeksn = 204 Obese adults without diabetes | About 3.6 kg placebo corrected weight loss at doses up to 240 ug three times daily | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Obesity and chronic weight management | Not graded | GLP-1 based peptides are the only peptides with large randomized trials for weight loss. Semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks and tirzepatide 15 mg produced 20.9% over 72 weeks. Retatrutide, cagrilintide, and survodutide are in late stage trials. |
| Type 2 diabetes | Evidence: Human RCT evidence | Amylin analog approved as an adjunct to mealtime insulin. |
| Type 1 diabetes | Evidence: Human RCT evidence | Lowered HbA1c by about 0.4 versus 0.1 percentage points on placebo, with about 1 kg less weight, as an insulin adjunct; carries a boxed warning for severe hypoglycemia. |
Is Pramlintide legal in the United States?
FDA and compounding status
FDA approved product (Symlin, March 2005) for type 1 and type 2 diabetes in patients using mealtime insulin who have not achieved glucose control. It is prescription only. Because an approved product is available and not in shortage, compounding is not permitted except for a documented patient specific clinical need. Pramlintide is not on any FDA compounding bulks list and is not sold through peptide vendors in any meaningful way.
WADA status
Not WADA prohibited. Not named on the current prohibited list. Athletes should still confirm against the list in force for their season.
Regulatory timeline
- FDA
FDA approves Symlin (pramlintide) as an adjunct to insulin
FDA approved pramlintide injection (Symlin), a synthetic amylin analog, for use with mealtime insulin in type 1 and type 2 diabetes.
Regulatory: FDA approvedSource: Drugs@FDA: Symlin (pramlintide) NDA 021332
Pramlintide dose on the FDA label
Doses below are quoted from the FDA label for its approved uses, plus the doses used in the pivotal trials where noted. The prescriber sets the dose; PeptideAgent does not recommend doses or protocols.
FDA label (Symlin, DailyMed): when starting, mealtime insulin is reduced by 50%. Type 1 diabetes: 15 mcg subcutaneously before major meals, increased in 15 mcg steps to a maintenance dose of 30 or 60 mcg as tolerated. Type 2 diabetes: 60 mcg before major meals, increased to 120 mcg as tolerated. The label advises at least 3 days between dose steps to limit nausea, and carries a boxed warning for severe hypoglycemia with insulin, occurring within 3 hours of an injection. Symlin and insulin are always given as separate injections.
Routes reported
| # | Route |
|---|---|
| 1 | Subcutaneous injection before major meals (pen device) |
What are the side effects and interactions of Pramlintide?
Side effects
| # | Reported side effect |
|---|---|
| 1 | Nausea (28 to 48% in trials, highest in type 1 diabetes and during titration) |
| 2 | Severe hypoglycemia when insulin is not reduced (boxed warning; risk within 3 hours of injection) |
| 3 | Reduced appetite and vomiting |
| 4 | Headache |
| 5 | Injection site reactions |
| 6 | Fatigue and dizziness |
Interactions
| # | Interaction |
|---|---|
| 1 | Insulin: mealtime insulin must be reduced by about 50% at initiation to prevent severe hypoglycemia |
| 2 | Oral medications that need rapid absorption (for example analgesics): take 1 hour before or 2 hours after pramlintide because of delayed gastric emptying |
| 3 | Anticholinergics and other drugs that slow gastric motility: additive effect, not recommended |
| 4 | GLP-1 receptor agonists: additive slowing of gastric emptying, combination not studied in labeling |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Confirmed gastroparesis |
| 2 | Hypoglycemia unawareness |
| 3 | Hypersensitivity to pramlintide or metacresol |
| 4 | Not for patients with poor adherence to insulin or glucose monitoring, or HbA1c above 9% (label warnings) |
How do people access Pramlintide legally?
Typical cost: List price is well over 1,000 USD per month for SymlinPen at typical doses; commercial insurance copays vary and coverage often requires prior authorization. Prices verified on the last verified date.
Verified access options
Step 1
Prescription from an endocrinologist or primary care provider filled at a retail or specialty pharmacy as Symlin.
Step 2
Not available through compounding pharmacies or telehealth peptide clinics.
Access paths are verified against public regulatory records and prescriber licensing. We never list unlicensed vendors.
Compare Pramlintide
Frequently asked questions
Does pramlintide help with weight loss?
Modestly. In 1 year diabetes trials it produced about 1 to 2 kg less weight than placebo while insulin alone caused weight gain. In a 16 week trial in 204 obese adults without diabetes, doses up to 240 ug three times daily gave about 3.6 kg placebo corrected weight loss. Its long acting cousin cagrilintide, combined with semaglutide, is the compound being developed for weight loss. [2] [3]
What are the side effects of pramlintide?
Nausea is the main one, affecting roughly 28 to 48% of trial participants and easing after titration. The serious risk is severe hypoglycemia in the 3 hours after injection when mealtime insulin is not reduced, which is why the label has a boxed warning and requires cutting mealtime insulin by half at the start. Headache, vomiting, and reduced appetite are also reported. [1] [4]
What is the pramlintide (Symlin) dose on the FDA label?
A subcutaneous injection before each major meal, with mealtime insulin cut by 50% at the start. Type 1 diabetes starts at 15 mcg and rises in 15 mcg steps to 30 or 60 mcg; type 2 diabetes starts at 60 mcg and rises to 120 mcg, waiting at least 3 days between steps. It is never mixed with insulin in the same syringe, and the boxed warning covers severe hypoglycemia within 3 hours of a dose. [4]
How much does pramlintide cost?
SymlinPen's list price is well over 1,000 USD per month at typical doses. Commercial and Medicare coverage varies and often requires prior authorization; manufacturer savings programs have been offered. Prices verified on the last verified date and change. [4]
Is pramlintide banned by WADA?
No. Pramlintide is not on the WADA Prohibited List. Insulin, which it is used alongside, is prohibited under section S4, so athletes with diabetes need a therapeutic use exemption for their insulin regardless. [5]
Pramlintide vs semaglutide: which is better for type 2 diabetes?
Semaglutide, for most people. It lowers HbA1c by 1 to 1.5 points, produces about 15% weight loss at the weight management dose, reduces cardiovascular events, and is given weekly. Pramlintide lowers HbA1c by about 0.3 to 0.4 points more than placebo, gives 1 to 2 kg of weight loss, needs injection before each meal, and works only alongside insulin. Pramlintide's niche is type 1 diabetes, where GLP-1 agonists are not approved. [1] [2]
Can pramlintide be used in type 1 diabetes?
Yes, and it is the main use. In a 52 week trial of 480 adults with type 1 diabetes, pramlintide added to insulin lowered HbA1c by about 0.4 points versus 0.1 with placebo and prevented weight gain. The trade-off is nausea and an early increase in severe hypoglycemia until insulin doses are adjusted. [1] [4]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]Whitehouse F et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 2002PubMed 11919132, 2002
- [2]Hollander PA et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2003PubMed 12610038, 2003
- [3]Aronne L et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese subjects: a phase 2, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab 2007PubMed 17504894, 2007
- [4]FDA prescribing information for Symlin (pramlintide acetate) injection, via DailyMedFDA, 2024
- [5]WADA Prohibited ListWADA, 2026
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 23). Pramlintide: evidence, legality, and access. https://peptideagent.ai/peptides/pramlintide- HTML link
<a href="https://peptideagent.ai/peptides/pramlintide">Pramlintide: evidence, legality, and access</a>, PeptideAgent, updated September 23, 2026.